Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?  by Gruben, Nanda et al.
Biochimica et Biophysica Acta 1842 (2014) 2329–2343
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bbad isReviewNonalcoholic fatty liver disease: A main driver of insulin resistance or a
dangerous liaison?☆Nanda Gruben a, Ronit Shiri-Sverdlov b, Debby P.Y. Koonen a, Marten H. Hofker a,⁎
a University of Groningen, University Medical Center Groningen, Department of Pediatrics, Molecular Genetics Section, Antonius Deusinglaan 1, 9713 AV Groningen, The Netherlands
b Maastricht University, Department of Molecular Genetics, PO Box 616, 6200 MD Maastricht, The NetherlandsAbbreviations: AKT (or PKB), protein kinase B; ATGL
CGI-58, comparative gene identiﬁcation 58; ChREBP, carb
binding protein; CPT1a, carnitine palmitoyl transfera
element-binding; DAG, diacylglycerol; DGAT2, acyl-CoA:d
ER, endoplasmic reticulum; FATP2, fatty acid transporter p
porter protein 5; GNMT, glycine N-methyltransferase; HO
sessment of insulin resistance; IκBα, inhibitor of NF-κB α
β; IL-1R, interleukin 1 receptor; IL-6Rα, interleukin-6 re
IRS1/2, insulin receptor substrate 1/2; JNK, c-Jun NH2
receptor; mTorc1, mammalian target of rapamycin co
trifunctional protein; MTTP, microsomal triglyceride tr
unsaturated fatty acid; MyD88, myeloid differentiatio
NASH, nonalcoholic steatohepatitis; NAFLD, nonalcoh
nuclear factor κB; NIK, NF-κB inducing kinase; NKT
NOX4, NAD(P)H oxidase homologue 4; OSM, oncostat
PKC, protein kinase C; PI3K, phosphatidylinositol 3-kinase;
RANK, receptor activator of NF-κB; RANKL, receptor activato
fatty acid; shRNA, short hairpin RNA; SOCS3, suppressor of
sterol regulatory element-binding protein 1c; T2D, type 2
TLR, Toll-like receptor; TNFα, tumor necrosis factorα; TNFR
TRAF2, TNF-receptor associated factor; VLDL, very low den
☆ Competing interests: The authors declare that they h
⁎ Corresponding author at: Molecular Genetics (HPC EA
Groningen, Antonius Deusinglaan 1, 9713 AV Groningen,
3637932; fax: +31 50 3617310.
E-mail addresses: n.gruben@umcg.nl (N. Gruben), r.sv
(R. Shiri-Sverdlov), d.p.y.koonen@umcg.nl (D.P.Y. Koonen
(M.H. Hofker).
http://dx.doi.org/10.1016/j.bbadis.2014.08.004
0925-4439/© 2014 Elsevier B.V. All rights reserved.a b s t r a c ta r t i c l e i n f oArticle history:
Received 15 May 2014
Received in revised form 2 August 2014
Accepted 7 August 2014
Available online 14 August 2014
Keywords:
Nonalcoholic fatty liver disease
Nonalcoholic steatohepatitis
Insulin resistance
Inﬂammation
Kupffer cell
LipidInsulin resistance is one of the key components of the metabolic syndrome and it eventually leads to the develop-
ment of type 2 diabetes, making it one of the biggest medical problems of modern society. Nonalcoholic fatty
liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) are tightly associated with insulin resistance.
While it is fairly clear that insulin resistance causes hepatic steatosis, it is not known if NAFLD causes insulin resis-
tance. Hepatic inﬂammation and lipid accumulation are believed to be themain drivers of hepatic insulin resistance
inNAFLD.Herewegive anoverviewof the evidence linking hepatic lipid accumulation to the development of insulin
resistance, including the accumulation of triacylglycerol and lipidmetabolites, such as diacylglycerol and ceramides.
In particular,we discuss the role of obesity in this relation by reviewing the current evidence in terms of the reported
changes in body weight and/or adipose tissue mass. We further discuss whether the activation or inhibition of
inﬂammatory pathways, Kupffer cells and other immune cells inﬂuences the development of insulin resistance.
We show that, in contrast to what is commonly believed, neither hepatic steatosis nor hepatic inﬂammation is suf-
ﬁcient to cause insulin resistance. Many studies show that obesity cannot be ignored as an underlying factor in this
relationship and NAFLD is therefore less likely to be one of the main drivers of insulin resistance.
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The easy availability of appealing food high in calories is driving ex-
cess nutrient intake and the development of obesity and the metabolic
syndrome.Oneof the key components of themetabolic syndrome is insu-
lin resistance, which precedes the development of type 2 diabetes (T2D)
[1]. Insulin resistance is reversible, but once T2D has established and
beta-cells are damaged, the disease progresses [2]. As the number of
people with T2D and healthcare costs continue to rise, it is important to
prevent the development of T2D by improving insulin sensitivity. How-
ever, much is still unclear about the mechanisms leading to insulin resis-
tance, which makes it difﬁcult to develop new and effective therapies.
Nonalcoholic fatty liver disease (NAFLD) is a feature of the metabolic
syndrome and is strongly associatedwith insulin resistance. InNAFLD, tri-
acylglycerols (TAGs) accumulate in the liver (hepatic steatosis) due to an
imbalance between lipid storage and lipid removal [3]. This is caused by a
higher dietary fat intake, increased de novo lipogenesis, and increased li-
polysis in adipose tissue [4]. In addition, macrophages and other immune
cells are recruited to the liver and secrete pro-inﬂammatory cytokines [5,
6]. This state of hepatic inﬂammation is known as nonalcoholic
steatohepatitis (NASH) and it can progress toward cirrhosis and hepato-
cellular carcinoma [4]. Because NAFLD has become a major disease bur-
den in Western society [7], it is important to determine the exact role of
NAFLD in the development of insulin resistance. Low-grade chronic in-
ﬂammation and lipid accumulation in the liver and other organs (ectopic
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resistance [8–10]. Therefore, hepatic steatosis and hepatic inﬂammation
in NAFLD are believed to contribute to insulin resistance as well [11].
However, since NAFLD is often accompanied by obesity in mouse
models, it is difﬁcult to differentiate the effects of obesity and NAFLD
on insulin resistance. Thus, it remains unclearwhether NAFLD is causal-
ly involved in the development of insulin resistance.
In this review, we discuss the evidence linkingNAFLD to hepatic and
systemic insulin resistance and explore the evidence for NAFLDhaving a
causal role in the development of insulin resistance. We speciﬁcally
discuss the role of hepatic lipid accumulation and hepatic inﬂammation.
We focus on the role of TAGs and lipidmetabolites, including diacylglyc-
erols (DAGs) and ceramides, and on the main inﬂammatory pathways,
including nuclear factor κB (NF-κB) and c-Jun NH2-terminal kinase
(JNK). We also discuss the role of Kupffer cells, since these are of partic-
ular importance in regulating hepatic inﬂammation. We highlight data
derived from studies using liver-speciﬁc mouse models and investigate
which effects are independent of bodyweight changes. Althoughmouse
studies are crucial in understanding disease mechanisms, no mouse
model fully captures human NAFLD. Thus, some of the mechanisms
we propose still need to be validated in man.
2. Hepatic lipid accumulation and insulin resistance
2.1. Evidence that insulin resistance causes hepatic lipid accumulation
There is a strong association between hepatic lipid accumulation and
insulin resistance. This association is at least partly caused by the dual
effect of insulin on hepatic glucose production (gluconeogenesis) and
de novo lipogenesis in the liver. The liver controls blood glucose homeo-
stasis by gluconeogenesis and this is inhibited by insulin. In hepatic in-
sulin resistance, the inhibition is no longer effective [12] and the
pancreas compensates for this by increasing the production of insulin
to maintain normal glucose levels. However, there is strong evidence
that insulin resistance is selective and only occurs for the pathway
involved in glucose metabolism, but not for de novo lipogenesis. The
increased insulin levels therefore overstimulate de novo lipogenesis,
leading to increased production of lipids (reviewed by [13]). In the
liver, the molecular basis for this mechanism was shown to involve
sterol regulatory element-binding protein (Srebp)-1c, an important
lipogenic transcription factor. While genes involved in glucose metabo-
lism were downregulated in models for insulin resistance, Srebp-1c
remained activated [14]. The inhibition of the gluconeogenic pathway
and activation of the lipogenic pathway both require activation of the
insulin receptor (IR) [15,16]. There must therefore be a point down-
stream of the IRwhere the glucose pathway and the lipogenesis pathway
diverge. Evidence for this branch point comes from a study in which the
inhibition of the mammalian target of rapamycin complex 1 (mTorc1),
which is required for lipid synthesis, selectively blocked lipogenesis, but
not the suppression of gluconeogenesis [17]. More recently, another
downstream target of the IR, NAD(P)H oxidase homologue 4 (Nox4)
has been implicated. Inactivation of this pathway by knockdown of
Nox4 in hepatocytes reduced the insulin-stimulated glucose uptake,
while lipogenesis was maintained [18]. However, a recent review
discussed the possibility that alterations in nutrient handling in periph-
eral tissues due to insulin resistance contributemore to the lipid pheno-
type in the liver than selective hepatic insulin resistance [19].
2.2. Evidence that hepatic lipid accumulation causes insulin resistance
Although the above studies indicate that insulin resistance causes
hepatic lipid accumulation, this does not exclude steatosis from also
being a cause of insulin resistance. Indeed, numerous studies, including
dietary intervention studies, have been reported in which hepatic
steatosis is accompanied by insulin resistance in mice (reviewed by
[20]). The possibility therefore arises that the relationship betweensteatosis and insulin resistance is a vicious cycle, in which systemic
insulin resistance leads to hepatic steatosis, and hepatic steatosis then
leads to an exacerbation of hepatic insulin resistance. In order to deter-
mine whether hepatic steatosis is a consequence or a cause of insulin
resistance, mouse models with liver-speciﬁc defects in genes involved
in hepatic lipid metabolism are of crucial importance. Below we de-
scribe the impact of alterations in fatty acid uptake, de novo lipogenesis,
beta-oxidation and VLDL-export on hepatic steatosis and insulin resis-
tance. See Fig. 1 and Box 1 for details of how these models ﬁt into the
pathways involved in hepatic lipid metabolism.
In support of a causal role for hepatic steatosis in the development of
insulin resistance, an improvement in hepatic steatosis and NAFLD was
associatedwith increased systemic insulin sensitivity inmicewith liver-
speciﬁc knockdown of fatty acid transporter protein 5 (Fatp5) [21].
Fatp5 is involved in the uptake of fatty acids from the blood. Moreover,
studies investigating important transcription factors for lipogenic genes
(Srebp-1c, and carbohydrate responsive element-binding protein
(Chrebp)) found a relationship between steatosis and insulin resistance
in liver-speciﬁc models [22,23]. Overexpression of Srebp-1c in mice in-
creased the homeostasis model assessment of insulin resistance
(HOMA-IR) 3-fold in parallel with an increase in steatosis [22], whereas
knockdownofChrebp in ob/obmice improved hepatic steatosis and sys-
temic insulin resistance [23]. In addition, mice fed with a high-fat diet
and with increased fatty acid oxidation driven by constitutively active
carnitine palmitoyl transferase 1a (Cpt1a) in the liver are protected
against the development of steatosis and hepatic and systemic insulin
resistance [24].
However, each of the above studies reported alterations in body
weight between the mice (Table 1). Due to the co-existing nature of
steatosis and insulin resistance with obesity, it is therefore likely that
the level of adiposity drives the etiology of insulin resistance in these
studies. Indeed, the importance of the effect of increased adiposity on
insulin resistance is well illustrated by a study in which mice lacking
tumor necrosis factor receptors (TNFRs) were more obese and more
insulin resistant than their wild type controls. After matching both
groups for body weight, the differences in insulin resistance between
them almost completely disappeared [25]. In addition, severe weight
loss and loss ofwhite adipose tissue are associatedwith improved insulin
sensitivity in mice fed a methionine- and choline-deﬁcient diet, a well-
characterized model for NAFLD [26].
In line with this, several studies in which body weight is not affect-
ed do not show a relationship between steatosis and insulin resistance
(Table 1, Fig. 1). Increased uptake of fatty acids by hepatic Cd36 over-
expression in mice resulted in increased hepatic TAG accumulation,
but did not affect glucose tolerance [27]. Similarly, treatment with an
agonist for the liver X receptor (Lxr), which activates Srebp-1c and
Chrebp, induced hepatic steatosis in lean and ob/ob mice, but this did
not affect their hepatic insulin resistance [28]. In addition, increases
in fatty acid oxidation in the liver by overexpression of Cpt1a, resulted
in a reduction in hepatic TAG content in rats. This was not associated
with changes in the HOMA-IR [29]. Moreover, liver-speciﬁc deletion
of adipose triacylglycerol lipase (Atgl), an enzyme involved in TAGpro-
cessing, increased steatosis in mice. However, hepatic insulin resis-
tance and systemic insulin resistance were not affected in this model
[30]. Another study also found a dissociation between hepatic steatosis
and insulin resistance. Enhancing hepatic fatty acid oxidation by ex-
pression of constitutively active Cpt1a improved hepatic insulin signal-
ing and glucose and insulin tolerance, without reducing the level of
hepatic steatosis [31].
Nevertheless, there are several studies that, in the absence of obesity
as a confounding factor, support a causal role for hepatic steatosis in the
development of insulin resistance. For instance, hepatic steatosis as a re-
sult of a 50% reduction inmitochondrial fatty acid oxidation is associated
with the development of systemic insulin resistance in agedmice [32]. In
this study, insulin resistance occurred at the same time point that
steatosis developed [32]. In addition, fatty liver Shionogi mice have
Fig. 1.Hepatic steatosis in the etiology of insulin resistance. Simpliﬁed overview of the pathways involved in lipid accumulation in the liver and their proposed roles in the development of
insulin resistance. Lipid accumulation occurs due to increased uptake of free fatty acids (1), increased de novo lipogenesis (2), reduced fatty acid oxidation (3) and/or reduced VLDL export
(4) (see Box 1 for details of hepatic lipid metabolism). The metabolites of these pathways are shown in brown. Proteins involved in hepatic lipid accumulation are shown in red and blue.
The red proteins have been implicated in the development of insulin resistance, whereas the blue proteins have been shown not to affect insulin resistance in at least one study. The
molecules that directly interfere with the insulin signaling pathway (gray) are shown in black. DAGs, ceramides and free fatty acids have been implicated in the etiology of insulin
resistance by inhibiting IRS1/2 and AKT signal transduction. DAGs (especially membrane associated) are believed to interfere with insulin signaling through activation of PKCε. Ceramides
have been shown to activate IKK2, JNK, PP2A and PKCζ, which all interfere with insulin signaling. Free fatty acids activate TLRs, which in turn activate IKK2, and IKK2 then inhibits IRS1.
Abbreviations: ACC, acetyl-CoA carboxylase; ACS, fatty acyl-CoA synthetase; AGPAT, 1-acylglycerol-3-phosphate acyltransferase; AKT (or PKB), protein kinase B; ATGL, adipose
triacylglycerol lipase; CGI-58, comparative gene identiﬁcation 58; ChREBP, carbohydrate responsive element-binding protein; CPT1a, carnitine palmitoyl transferase 1a; CPT2, carnitine
palmitoyl transferase 2; DAG, diacylglycerol; DGAT2, acyl-CoA:diacylglycerol acyltransferase 2; ER, endoplasmic reticulum; FA, fatty acid; FAS, fatty acid synthase; FATP2, fatty acid
transporter protein 2; FATP5, fatty acid transporter protein 5; FFA, free fatty acid; GPAT, glycerol-3-phosphate acyltransferase; HDL, high-density lipoprotein; IKK2, inhibitor
of κB-kinase-β; IR, insulin receptor; IRS1/2, insulin receptor substrate 1/2; JNK, c-Jun NH2-terminal kinase; LDL, low-density lipoprotein; LXR, liver X receptor; MTP, mitochondrial
trifunctional protein; MTTP, microsomal triglyceride transfer protein; PC, phosphatidylcholine; PKC, protein kinase C; PLC, phospholipase C; PP2A, protein phosphatase 2A; SREBP-1c,
sterol regulatory element-binding protein 1c; TAG, triacylglycerol; TCA, tricarboxylic acid cycle; TLR, Toll-like receptor; VLDL, very low density lipoprotein.
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pression of microsomal triglyceride transfer protein (Mttp). This has
been shown to induce hepatic steatosis accompanied by systemic insulin
resistance in thesemice [33]. Likewise, reductions in hepatic steatosis are
associated with a protection against systemic insulin resistance in mice
lacking hepatic fatty acid transporter protein 2 (Fatp2) [34] as well as
in db/dbmice with constitutively active Cpt1a in the liver [24]. However,
in mice lacking Fatp2, a reduction in fat pad weight was observed, even
though body weight was similar [34], which may explain the protection
against insulin resistance found in this study.
Together, these studies show that the relationship between
steatosis and insulin resistance is still controversial. For each of the
mechanisms that can contribute to steatosis,many studiesﬁnd conﬂict-
ing evidence for a relationship with insulin resistance (Fig. 1). In only a
few studies, insulin resistance was increased in line with enhanced
steatosis, independent of body weight gain (Table 1). Overall, hepatic
steatosis in itself does not seem to be sufﬁcient or necessary to inducehepatic insulin resistance [35], suggesting that it is not a main driver
of insulin resistance.
2.3. Lipid species and insulin resistance
A possible explanation for the contradictory ﬁndings underlying the
relationship between hepatic steatosis and insulin resistance is that
hepatic steatosis is a generalmeasure, referring to the buildup of neutral
lipids, such as TAGs and cholesterol esters, in lipid droplets in hepato-
cytes. The accumulation of lipid species and metabolites, such as
DAGs, ceramides and saturated fatty acids (SFAs), is more closely linked
to the development of insulin resistance [9,10,35,36]. Indeed, a correla-
tion between the accumulation of harmful lipid metabolites in the liver
and hepatic insulin resistance has been observed in several animal
models (Table 2). DAGs are used for the formation of TAGs and this pro-
cess is catalyzed by the enzyme acyl-CoA:diacylglycerol acyltransferase
2 (Dgat2) [37]. Manipulations in this enzyme therefore affect DAG and
Box 1
Hepatic lipid metabolism.
FFA are transported across the plasma membrane by FATP2,
FATP5 and CD36 and are converted to ceramides or to acyl-CoA.
Acyl-CoAs are also formed during de novo lipogenesis. SREBP-1c
and ChREBP are transcription factors for de novo lipogenic genes.
The activity of these transcription factors is stimulated by LXR.
Acyl-CoAs are transported to themitochondria for fatty acid oxida-
tion or are incorporated in TAG. During fatty acid oxidation, CPT1a
and CPT2 facilitate the transport of acyl-CoA across the outer and
inner mitochondrial membranes. The last three steps of the oxida-
tion of fatty acids in the tricarboxylic acid cycle are catalyzed by
MTP. TAGs are formed from Acyl-CoA in multiple steps, with
DAG as one of the intermediate metabolites. Once DAG is formed,
DGAT2 catalyzes the final step toward TAG synthesis. In addition,
PC, derived from HDL and LDL, is converted to DAG by PLC and
then further converted to TAG. VLDL particles are assembled from
TAGs and ApoB100 with the help of MTTP in the ER. In addition,
TAGs are stored in lipid droplets, fromwhich they can bemobilized
by ATGL and its activator CGI-58.
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tion in liver TAG andDAGcontent and protects against the development
of hepatic and systemic insulin resistance [38]. In support of the
detrimental role of DAGs in insulin resistance, Chan et al. showed that
a reduction in hepatic DAG by fenoﬁbrate treatment improved glucose
intolerance and restored hepatic insulin signaling in mice [39].
However, in these studies, the protection against insulin resistance
occurred in parallel with a decrease in body weight, suggesting that
the effects on hepatic and systemic insulin resistance are caused by al-
terations in adiposity and not by alterations in lipid species. Consistent
with this, several other studies in which body weight is not a confound-
ing factor do not show a relationship between lipid species and insulin
resistance (Table 2, Fig. 2). Increased levels of TAGs, DAGs and ceramides
byhepaticDgat2 overexpression inmice did not affect hepatic or system-
ic insulin resistance [40]. In addition, Minehira et al. showed that
blocking VLDL secretion in mice by hepatic deletion of Mttp and the
resulting increase in TAGs, DAGs and ceramides did not induce hepatic
or systemic insulin resistance [41]. Similarly, knockdown of comparative
gene identiﬁcation 58 (CGI-58) in the liver of mice on a chow diet, led to
the accumulation of lipid species,withoutworsening systemic insulin re-
sistance [42]. Phosphatidylcholine (PC), half of which is derived from li-
poproteins, is an important source of TAG in the liver [43]. Interference in
PC metabolism, by knocking down glycine N-methyltransferase (Gnmt),
also did not result in systemic insulin resistance, even though hepatic
TAG and DAG levels were elevated [44]. Additional evidence against a
role for lipid species in the development of insulin resistance comes
from mice heterozygote for mitochondrial trifunctional protein (Mtp).
These mice have a 50% reduction in fatty acid oxidation, that leads to a
reduction in ceramides, but an increase in hepatic insulin resistance
[45]. Moreover, mice with increased TAGs and DAGs due to liver-
speciﬁc overexpression of Chrepb were protected against the
development of hepatic and systemic insulin resistance [46]. Despite
the fact that their body weight was not altered, their fat mass was
decreased [46], which may partly explain the protection against insulin
resistance observed in this study. Another explanation may be the en-
richment of beneﬁcial lipid species (mono-unsaturated fatty acids,
MUFAs) and the reduction of detrimental lipid species (SFAs) found in
mice overexpressing Chrebp in the liver [46].
Of note, there are only a few studies that report that lipid species in-
duce insulin resistance, independent of bodyweight (Table 2). Strikingly,
a group, using the same mouse model of Dgat2 overexpression in the
liver as previously described [40], found that these mice have increasedhepatic TAGs, ceramides and DAGs, and exacerbated hepatic, but not
systemic, insulin resistance [47]. Similarly, a modiﬁcation in another
enzyme involved in TAG processing shows a relationship between lipid
metabolites and insulin resistance. Mice in which Atgl is overexpressed
in the liver have reduced steatosis and a decreased amount of DAGs
and ceramides in the liver, associated with a mild improvement of
hepatic insulin signaling [48].
Despite this controversy, there is much evidence for the mecha-
nisms by which these lipid metabolites may interfere with the insulin
signaling cascade (Fig. 1). Following insulin binding to the IR, the IR in-
duces tyrosine phosphorylation of the insulin receptor substrates (IRS1
and IRS2). At these phosphorylation sites, other signaling molecules,
such as phosphatidylinositol 3-kinase (PI3K), bind and transmit the
signal further to protein kinase B (PKB or AKT) [9]. Ceramides induce
protein kinase C (PKC)ζ and protein phosphatase 2A (PP2A) activation
(reviewed by [36]). PKCs and PP2A have been shown to interfere with
insulin signaling [49–52]. In addition, ceramides were shown to up-
regulate kinases that are believed to inhibit insulin signaling, includ-
ing JNK and inhibitor of κB-kinase-β (IKK2) [53–55]. In adipocytes,
ceramides and glucosylceramides were found to antagonize insulin
action, whereas in myotubes only ceramides seemed to play a role
[56]. Glucosylceramides also do not seem to be important in the liver,
as liver-speciﬁc inhibition of glucosylceramide synthesis did not im-
prove insulin resistance in mice [57]. If another class of ceramides
does interfere with insulin signaling in the liver, it is still unknown.
Speciﬁc DAG species, e.g. sn-1,2 DAGs, are also believed to activate
PKC [58]. In the liver, particularly PKCε has been implicated [59]. SFAs
were shown to induce insulin resistance through DAG-induced PKCε
activation, independent of ceramides, and PKCε impaired IRS2 signaling
[60]. That PKCε is responsible for the observed effect on insulin resis-
tance is supported by the fact that antisense oligonucleotide-mediated
inhibition of PKCε in the liver improved insulin resistance, independent
of DAG levels [61]. In addition, DAGswere shown to benecessary for en-
doplasmic reticulum (ER)-stress to induce hepatic insulin resistance
[39]. Finally, lipid species may induce inﬂammation through the activa-
tion of Toll-like receptors (TLRs) and could thereby cause insulin resis-
tance indirectly [62].2.4. Hepatic lipid accumulation and insulin resistance: unresolved questions
The relationship between steatosis and insulin resistance is still
controversial (Fig. 1). In many studies the relationship between
steatosis and systemic as well as hepatic insulin resistance is explained
by adiposity. However, there is also evidence that hepatic lipids induce
insulin resistance under certain circumstances. Unfortunately, the com-
plex andmultifactorial etiology of insulin resistancemakes it difﬁcult to
elucidate what these speciﬁc circumstances are. Since C57BL/6 mice
were used in the majority of studies (Tables 1 and 2), environmental
factors, such as gut microbiota or breeding circumstances, are likely to
be involved. The fact that two groups using the same mouse model, at
the same age and on the same diet, found contradictory results [40,47]
emphasizes this point. Determining the factors that explain the differ-
ences between these two studies would help us to understand which
environmental factors are involved in the development of insulin resis-
tance and/or which experimental procedures are the most reliable. In
addition, it may depend on the fatty acid composition in the liver, as
an increase in the hepatic MUFA/SFA ratio was associated with protec-
tion against metabolic disease, despite high DAG levels [46]. On the
other hand, other authors reported that increased MUFAs in the liver
are associated with worsened insulin resistance [22]. Thus, the role of
the fatty acid composition in insulin resistance warrants further investi-
gation. In addition, it would be of interest to determine if the fatty acid
composition of TAGs and DAGs is relevant in the development of insulin
resistance, as alterations in their fatty acid composition have been
shown to occur in patients with NAFLD [63].
Table 1
Animal models investigating hepatic steatosis and insulin resistance.
Mechanism Modela Dietb Steatosis Body
weight
Insulin resistance Assessed by Ref.
Fatty acid uptake FATP5 knockdown liver using AAV HFD (60% fat) Decreased Decreased Systemic IR decreased Glucose levels, GTT, ITT [21]
CD36 overexpression liver using AV LFD (10% fat) Increased Not affected Systemic IR not affected Glucose levels, GTT [27]
FATP2 knockdown liver using AAV HFD (60% fat) Decreased Not affectedc Systemic IR decreased Glucose levels, GTT, HOMA-IR [34]
De novo lipogenesis SREBP-1c overexpression liver using
transgenic approach
Standard chow Increased Increased Systemic IR increased HOMA-IR, QUICKI [22]
ChREBP knockdown liver using AV
in ob/ob mice
Standard chow Decreased Decreased Systemic IR decreased Glucose and insulin levels, GTT, ITT,
WAT and muscle insulin signaling
[23]
LXR agonist in diet Standard chow Increased Not affected Systemic and hepatic
IR not affected
Glucose and insulin levels, HIEC, hepatic
gene expression
[28]
Standard chow (ob/ob) Increased Not affected Systemic IR decreased,
hepatic IR not affected
Glucose and insulin levels, HIEC, hepatic
gene expression
Beta-oxidation Constitutively active CPT1a liver using
AAV in DIO or db/db mice
HFD (60% fat) Decreased Decreased Hepatic and systemic
IR decreased
Glucose and insulin levels, GTT, PTT,
hepatic, muscle and WAT insulin signaling,
hepatic gene expression
[24]
Chow (db/db mice) Decreased Not affected Decreased systemic IR Glucose and insulin levels
CPT1a overexpression liver using AV in
Sprague–Dawley rats
Standard chow Decreased Not affected Systemic IR not affected Glucose and insulin levels, HOMA-IR [29]
HFD (41% fat) Decreased Not affected Systemic IR not affected Glucose and insulin levels, HOMA-IR
Constitutively active CPT1a liver using
AV in DIO or ob/ob mice
Chow (ob/ob mice) Not affected Not affected Systemic IR decreased Insulin levels, GTT, ITT [31]
HF/HSD (35% CHO, 45% fat) Not affected Not affected Hepatic and systemic
IR decreased
Insulin levels, GTT, ITT, hepatic insulin
signaling
MTP heterozygote mice Standard chow young Not affected Not affected Systemic IR not affected Glucose and insulin levels, GTT, ITT [32]
Standard chow aged Increased Not affected Systemic IR increased Glucose and insulin levels, GTT, ITT
VLDL export Fatty liver Shionogi mice Standard chow Increased Not affected Systemic IR increased HOMA-IR [33]
Lipolysis ATGL knockdown liver Standard chow Increased Not affected Hepatic and systemic
IR not affected
Glucose levels, GTT, ITT, PTT,
hepatic gene expression
[30]
HFD (59% fat) Increased Not affected Systemic IR not affected GTT, ITT
Abbreviations: AAV, adeno-associated virus; ATGL, adipose triacylglycerol lipase; AV, adenovirus; CHO, carbohydrate; ChREBP, carbohydrate responsive element-binding protein; DIO, diet-induced obese; FATP2, fatty acid transporter protein 2; FATP5, fatty
acid transporter protein 5; GTT, glucose tolerance test; HFD, high fat diet; HF/HSD, high fat/high sucrose diet; HIEC, hyperinsulinemic–euglycemic clamp; HOMA-IR, homeostasis model assessment of insulin resistance; ITT, insulin tolerance test; IR, insulin
resistance; LFD, low-fat diet; LXR, liver X receptor;MTP,mitochondrial trifunctional protein; PTT, pyruvate tolerance test; ref, reference; SREBP-1c, sterol regulatory element-binding protein 1c; VLDL, very lowdensity lipoprotein;WAT,white adipose tissue.
a All models were mice on a C57BL/6 background, unless otherwise stated.
b All percentages are calories from fat, unless otherwise stated.
c Body weight not affected, but decreased adipose tissue mass.
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Table 2
Animal models investigating hepatic lipid species and metabolites in the development of insulin resistance.
Modela Dietb Hepatic
inﬂammation
Lipid accumulation Body
weight
Insulin
resistance
Assessed by Ref.
DGAT2 hepatic knockdown
using ASOs in Sprague–Dawley rats
HFD (59% fat) n.d. Decreased: TAGs and DAGs;
not affected: long-chain acyl CoAs
Decreased Hepatic and systemic
IR decreased
Glucose and insulin levels,
HIEC, hepatic insulin signaling
[38]
PPARα activation using fenoﬁbrate HFruD (35% fructose) Not affected Decreased: TAGs and DAGs;
increased: ceramides
Decreased Hepatic and systemic
IR decreased
Glucose and insulin levels, GTT,
HOMA-IR, hepatic and muscle insulin signaling
[39]
DGAT2 hepatic overexpression
using transgenic approach
Standard chow Not affected Increased: TAGs, DAGs,
ceramides and long chain acyl CoA
Not affected Hepatic and systemic
IR not affected
Glucose and insulin levels, GTT, ITT, HIEC,
hepatic insulin signaling
[40]
MTTP knockdown liver
(C57BL/6 and 129/SvJae mix)
Standard chow n.d. Increased: TAGs, DAGs and ceramides Not affected Hepatic and systemic
IR not affected
Glucose and insulin levels, GTT, HIEC,
hepatic insulin signaling and gene expression
[41]
CGI-58 knockdown using
ASOs liver and WAT
Standard chow Not affected Increased: TAGs, DAGs and ceramides;
not affected: long chain acyl CoAs
Not affectedc Systemic IR not affected Glucose levels, GTT, ITT, hepatic gene expression [42]
HFD (45% fat) Not affected Increased TAGs, DAGs, ceramides;
decreased: long chain acyl CoAs
Decreasedc Systemic IR decreased Glucose and insulin levels, GTT, ITT,
hepatic gene expression
GNMT knock-out mice Standard chow n.d. Increased: TAGs and DAGs Not affectedc Systemic IR not affected GTT, ITT [44]
MTP heterozygote mice Standard chow Not affected Increased: TAGs; not affected:
DAGs; decreased ceramides
Decreased Hepatic IR increased Glucose and insulin levels, HIEC,
hepatic insulin signaling and gene expression
[45]
ChREBP overexpression liver using AV Standard chow Decreased Increased: TAGs, DAGs and MUFAs;
not affected: ceramides, SFAs and PUFAs
Not affectedc Hepatic and systemic
IR decreased
Glucose and insulin levels, GTT, ITT, PTT,
hepatic insulin signaling and gene expression
[46]
HFD (60% fat, modiﬁed) Not affected Increased: TAGs, DAGs and MUFAs;
decreased: SFAs
Not affectedc Hepatic and systemic
IR decreased
Glucose and insulin levels, GTT,
hepatic insulin signaling and gene expression
DGAT2 hepatic overexpression using
transgenic approach
Standard chow Not affected Increased TAGs, DAGs and ceramides Not affected Hepatic IR increased,
systemic IR not affected
Insulin levels, HIEC, hepatic insulin signaling [47]
ATGL overexpression using AV HFD (59% fat) Not affected Decreased: TAGs, DAGs and ceramides Not affected Hepatic IR decreased Glucose and insulin levels, ITT, PTT,
hepatic insulin signaling and gene expression
[48]
Abbreviations: ASO, antisense oligonucleotide; ATGL, adipose triacylglycerol lipase; AV, adenovirus; CGI-58, comparative gene identiﬁcation 58; ChREBP, carbohydrate responsive element-binding protein; DAGs, diacylglycerols; DGAT2, acyl-CoA:
diacylglycerol acyltransferase 2; GNMT, glycine N-methyltransferase; HFD, high fat diet; HFruD, high fructose diet; HIEC, hyperinsulinemic-euglycemic clamp; HOMA-IR, homeostasis model assessment of insulin resistance; IR, insulin resistance; ITT,
insulin tolerance test; GTT, glucose tolerance test; MTP, mitochondrial trifunctional protein; MTTP, microsomal triglyceride transfer protein; MUFA, mono-unsaturated fatty acid; n.d., not determined; PPARα, peroxisome proliferator-activated re-
ceptor α; PTT, pyruvate tolerance test; ref, reference; PUFA, poly-unsaturated fatty acid; SFA, saturated fatty acid; TAGs, triacylglycerols; VLDL, very low density lipoprotein; WAT, white adipose tissue.
a All models were mice on a C57BL/6 background, unless otherwise stated.
b All percentages are calories from fat, unless otherwise stated.
c No differences in body weight, but decreased adipose tissue mass.
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Fig. 2.Hepatic inﬂammation in the etiology of insulin resistance. Simpliﬁed overview of the pathways involved in the development of inﬂammation and insulin resistance in hepatocytes.
The proteins involved in hepatic inﬂammation are shown in red and blue. The red proteins were shown to affect the development of insulin resistance, whereas the blue proteins were
shown not to affect insulin resistance in at least one study. The proteins involved in the insulin signaling pathway are shown in gray. Kupffer cells secrete OSM, which interferes with AKT
phosphorylation via activation of SOCS3 and STAT3 pathway. In addition, activatedKupffer cells secrete TNFα, which binds to TNFR1/2. Activation of TLR, IL-1R or the TNFR1 and/or 2 leads
to the activation of adaptors proteins, such asMyD88 and TRAF2. These adaptor proteins transmit the signal IKK2, JNK or NIK. IKK2 is also activated by RANK signaling, but inhibited by
IL-6Rα signaling. IKK2 activation results in the ubiquitination and subsequent degradation of IκBα. This releases NF-κB, which then translocates to the nucleus and starts the
transcription of pro-inﬂammatory genes. JNK activates the transcription factor AP-1, resulting in the transcription of pro-inﬂammatory genes. IKK2, JNK and the pro-inﬂammatory genes are
believed to interfere with insulin signaling at the level of IRS1/2 and AKT. NIK activates NF-κB and improves CREB stability. CREB promotes glucagon-induced gluconeogenesis. Abbreviations:
AKT (or PKB), protein kinase B; AP1, activator protein 1; CREB, cAMP response element-binding; IκBα, inhibitor of NF-κBα; IKK2, inhibitor of κB-kinase-β; IL-1R, interleukin 1 receptor; IL-6Rα,
interleukin-6 receptorα; IR, insulin receptor; IRS1/2, insulin receptor substrate 1/2; JNK, c-Jun NH2-terminal kinase;MyD88, myeloid differentiation primary response gene 88; NF-κB, nuclear
factorκB;NIK, NF-κB inducing kinase;OSM, oncostatinM;RANK, receptor activator ofNF-κB; SOCS3, suppressor of cytokine signaling 3; STAT3, signal transducer and activator of transcription3;
TLR, Toll-like receptor; TNFα, tumor necrosis factor α; TNFR1/2, tumor necrosis factor receptor 1/2; TRAF2, TNF-receptor associated factor.
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tion and insulin resistance found in several studies could lie in differ-
ences in the intracellular localization of lipid species [35]. It seems that
only membrane-associated DAGs are responsible for PKC inhibition.
The dissociation between DAGs and insulin resistance in mice treated
with antisense oligonucleotides to inhibit CGI-58 [42] was later ex-
plained by the fact that DAG levels were increased only in lipid droplets
and not in the cell membrane [64]. Since the localization of lipid species
has not been published in most studies, it is unclear whether this ex-
plains the discrepancies between the other studies. Future studies
need to elucidate the other circumstances under which lipids induce
insulin resistance.
3. Hepatic inﬂammation
3.1. Does hepatic inﬂammation cause hepatic insulin resistance?
Many animal models have been developed to gain insight into the
role of hepatic inﬂammation in the etiology of insulin resistance
(Tables 3 and 4, Fig. 2). In the sections below, we will describe the
data on the role of themain inﬂammatory pathways in thedevelopment
of insulin resistance.3.1.1. IKK2–NF-κB and insulin resistance
NF-κB is one of the most important transcription factors of inﬂam-
matory cytokines and is activated in NASH [65]. In addition, NF-κB acti-
vation has been implicated in the etiology of insulin resistance [66],
suggesting that its activation in NASH could also be important for insu-
lin resistance. The canonical pathway involved in NF-κB activation is
regulated by IKK2 (Fig. 2). When IKK2 becomes activated, it phosphor-
ylates the inhibitor of NF-κB, IκBα, which then becomes ubiquitinated
and subsequently degraded. This releases NF-κB for translocation into
the nucleus and initiates the transcription of pro-inﬂammatory genes
[67]. In a mouse model, Cai et al. found that a constitutively active
formof IKK2 led to hepatic inﬂammation andhepatic aswell as systemic
insulin resistance [68]. In line with this, knockdown of IKK2 in hepato-
cytes protected mice from hepatic insulin resistance [69], indicating
that hepatic inﬂammation induced by IKK2 plays an important role in
the development of insulin resistance. Upstream signals that activate
the IKK2/NF-κB pathway are mediated by the TLR and interleukin 1 re-
ceptor (IL-1R). Both TLR and IL-1R activate IKK2 via myeloid differenti-
ation primary response gene 88 (MyD88), making it a key molecule in
the activation of this pathway [70]. These proteins have also been inten-
sively studied in relation to insulin resistance. IL-1R-deﬁcientmicewere
protected from diet-induced systemic insulin resistance, without a
Table 3
Animal models investigating the role of hepatic inﬂammation in insulin resistance.
Pathway Modela Dietb Steatosis Hepatic
inﬂammation
Adipose tissue
inﬂammation
Body
weight
Insulin resistance Assessed by Ref.
NF-κB Constitutively active human IKK2 in
hepatocytes
Standard chow Decreased Increased n.d. Not
affected
Hepatic and systemic IR
increased
Glucose and insulin levels, GTT, HIEC, HOMA-IR, hepatic and muscle
insulin signaling and hepatic gene expression
[68]
Hepatocyte-speciﬁc knockdown of IKK2
in DIO or ob/ob mice
Standard chow n.d. Not affected Not affected n.d. Not affected Glucose and insulin levels, GTT, HIEC, hepatic insulin signaling and
gene expression
[69]
HFD (60% fat) n.d. Decreased Not affected n.d. Hepatic IR decreased,
systemic IR not affected
Glucose and insulin levels, GTT, HIEC, hepatic insulin signaling and
gene expression
Standard chow (ob/ob) n.d. n.d. Not affected n.d. Hepatic IR decreased,
systemic IR not affected
Glucose and insulin levels, GTT, HIEC, hepatic insulin signaling
TLR9 knockout mice CDAA diet (14% fat) Decreased Decreased n.d. Decreased Systemic IR decreased HOMA-IR [71]
IL-1R knockout mice CDAA diet (14% fat) Decreased Not affected n.d. Not
affectedc
Systemic IR decreased HOMA-IR
MyD88 knockout mice CDAA diet (14% fat) Decreased Decreased n.d. Not
affectedc
Systemic IR decreased HOMA-IR
TLR2 knockout mice Standard chow Decreased Not affected Not affected Not
affected
Systemic and hepatic IR
decreased
Glucose and insulin levels, GTT, ITT, PTT, HOMA-IR, hepatic, WAT and
muscle insulin signaling
[72]
HFD (60% fat) n.d. Decreased Decreased Decreased Systemic and hepatic IR
decreased
Glucose and insulin levels, GTT, ITT, HOMA-IR, hepatic, WAT and
muscle insulin signaling
MyD88 knockout mice Standard chow n.d. Not affected n.d. Not
affected
Systemic IR increased Glucose and insulin levels, GTT [73]
HFD (60% fat) n.d. Inconsistent n.d. Not
affected
Systemic IR increased Glucose and insulin levels, GTT
IκBα super-repressor expression in
liver db/db mice using AV
Standard chow Increased Not affected n.d. Not
affected
Hepatic IR decreased Glucose and insulin levels, GTT, PTT, HOMA-IR, hepatic insulin
signaling and gene expression
[78]
TNFR1/2 TNFR1 knockout mice Standard chow n.d. n.d. n.d. Decreased Systemic IR not affected Insulin levels, GTT, ITT [80]
HFD (55% fat) n.d. n.d. n.d. Decreased Systemic IR decreased Insulin levels, GTT, ITT
TNFα knockout mice (C57BL/6 and 129
mix)
Standard chow n.d. n.d. n.d. Not
affected
Systemic IR not affected,
hepatic IR not affected
Glucose and insulin levels, GTT, ITT [81]
HFD (60% fat) n.d. n.d. n.d. Not
affectedc
Systemic IR decreased,
hepatic IR not affected
Glucose and insulin levels, GTT, ITT, WAT, muscle and liver insulin
signaling
Ob/ob TNFR1/2 double knockout mice Standard chow n.d. n.d. n.d. Not
affected
Systemic IR decreased,
hepatic IR not affected
Glucose and insulin levels, GTT, ITT
TNFR1/2 double knockout mice HF/HSD (35.5% w/w fat,
36.6% w/w CHO)
n.d. n.d. Decreased Increased Systemic IR increased Glucose and insulin levels, GTT, ITT [25]
TNFR1 knockout mice HF/HSD (35.5% w/w fat,
36.6% w/w CHO)
n.d. n.d. n.d. Not
affected
Systemic IR not affected Glucose and insulin levels, GTT, ITT [82]
TNFR2 knockout mice HF/HSD (35.5% w/w fat, n.d. n.d n.d. Decreased Systemic IR not affected Glucose and insulin levels, GTT, ITT
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36.6% w/w CHO)
TNFR1/2 double knockout mice HF/HSD (35.5% w/w fat,
36.6% w/w CHO)
n.d. n.d. n.d. Not
affected
Systemic IR increased Glucose and insulin levels, GTT, ITT
Db/db TNFR1 knockout mice Standard chow n.d. n.d. n.d. Not
affected
Systemic IR not affected Glucose and insulin levels, GTT, ITT
TNFR1 deletion in aromatase knockout
mice
Phytoestrogen-low chow Increased n.d. n.d. Not
affected
Systemic IR increased Glucose and insulin levels, GTT, ITT [83]
TNFR1 gain of function mutation Standard chow Not
affected
Increased Not affected Not
affected
Systemic and hepatic IR not
affected
Insulin levels, GTT, hepatic insulin signaling and gene expression [84]
HFD (36% w/w fat) Not
affected
Increased Not affected Not
affected
Hepatic and systemic IR not
affected
Insulin levels, GTT, hepatic insulin signaling and gene expression
Hepatocyte-speciﬁc knockdown of
TRAF2
Standard chow n.d. n.d. n.d. Not
affected
Hepatic and systemic IR not
affectedd
Glucose and insulin levels, GTT, ITT, hepatic insulin signaling [85]
HFD (60% fat) Not
affected
Not affected n.d. Not
affected
Hepatic and systemic IR not
affectedd
Glucose and insulin levels, GTT, ITT, PTT, hepatic insulin signaling and
gene expression
Other Inhibition of NIK in the liver using AV HFD (45% fat) n.d. n.d. n.d. Not
affected
Hepatic and systemic IR not
affectedd
Glucose and insulin levels, GTT, ITT, PTT [87]
Hepatocyte-speciﬁc overexpression NIK Standard chow n.d. n.d. n.d. n.d. Hepatic and systemic IR not
affectedd
GTT, PTT, hepatic gene expression
Hepatocyte-speciﬁc knockdown of
RANK in DIO
Standard chow Not
affected
n.d. n.d. Not
affected
Hepatic and systemic IR not
affected
Glucose and insulin levels, GTT, ITT, HOMA-IR, HIEC, hepatic insulin
signaling
[89]
HFD (58% fat) Decreased n.d. n.d. Not
affected
Hepatic and systemic IR
decreased
Glucose and insulin levels, GTT, ITT, HOMA-IR, HIEC, hepatic insulin
signaling
Inhibition of RANK in the liver using
lentivirus
HFD (58% fat) n.d. Decreased n.d. n.d. Hepatic and systemic IR
decreased
Glucose and insulin levels, HOMA-IR, HIEC
JNK Overexpression of WT-JNK in liver
using AV
Standard chow n.d. n.d. n.d. Not
affected
Hepatic IR increased,
systemic IR not affected
Glucose and insulin levels, GTT, HIEC, hepatic insulin signaling and
gene expression
[91]
Overexpression DN-JNK in liver using
AV in db/db mice
Standard chow n.d. n.d. n.d. Not
affected
Hepatic IR decreased,
systemic IR not affected
Glucose and insulin levels, ITT, HIEC, hepatic insulin signaling and gene
expression
Overexpression DN-JNK in liver using
AV in DIO
HF/HSD n.d. n.d. n.d. Not
affected
Systemic IR decreased Glucose and insulin levels, GTT
JNK knockdown in liver using AV HFD (60% fat) Not
affected
n.d. n.d. Not
affected
Hepatic and systemic IR
decreased
Glucose and insulin levels, ITT, hepatic insulin signaling and gene
expression
[92]
Hepatocyte-speciﬁc knockdown of JNK Standard chow Increased Increased n.d. Not
affected
Hepatic IR increased,
systemic IR not affected
Glucose and insulin levels, GTT, HIEC, hepatic insulin signaling and
gene expression
[94]
HFD (60% fat) Not
affected
n.d. n.d. n.d. Hepatic and systemic IR not
affected
Glucose and insulin levels GTT, ITT, HIEC
Abbreviations: AV, adenovirus; CDAA, choline-deﬁcient L-amino acid deﬁned diet; CHO, carbohydrate; DIO, diet-induced obese; DN-JNK, dominant-negative type JNK; GK, Goto-Kakizaki; HFD, high fat diet; HF/HSD, high fat/high sucrose diet; IκBα,
inhibitor of NF-κBα; IKK2, inhibitor of κB-kinase-β; IL-1R, interleukin 1 receptor; IL-1Ra, interleukin 1 receptor antagonist; JNK, c-Jun NH2-terminal Kinase;MyD88,myeloid differentiation primary response gene 88; n.d., not determined; NIK, NF-κB
inducing kinase; TNFα, tumor necrosis factorα; NF-κB, nuclear factor κB; RANK, receptor activator of NF-κB; ref, reference; TLR, toll-like receptor; TNFR1, tumor necrosis factor receptor 1; TNFR2, tumor necrosis factor receptor 2; TRAF2, TNF-receptor
associated factor 2; WT-JNK, wild type JNK.
a All models were mice on a C57BL/6 background, unless otherwise stated.
b All percentages are calories from fat, unless otherwise stated.
c No changes in body weight, but decreased adipose tissue mass.
d The effects on glucose metabolism were mediated by glucagon.
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Table 4
Animal models investigating the role of Kupffer cells and other immune cells in insulin resistance.
Modela Dietb Steatosis Hepatic
inﬂammation
Adipose tissue
inﬂammation
Body
weight
Insulin resistance Assessed by Ref.
GdCl3 KC depletion in Wistar rats HFD (45% fat) Decreased Decreased Not affected Not
affected
Hepatic IR decreased,
systemic IR not affected
Glucose and insulin levels, HIEC [96]
HSD (68% sucrose) Decreased Decreased Not affected Not
affected
Hepatic IR decreased,
systemic IR not affected
Glucose and insulin levels, HIEC
GdCl3 KC depletion Standard chow Not
affected
Decreased Not affected Not
affectedc
Hepatic and systemic IR
decreased
Glucose and insulin levels, GTT, HOMA-IR, hepatic
insulin signaling and gene expression
[98]
HFD (72% fat) Decreased n.d. n.d. Decreased Hepatic and systemic IR
decreased
Glucose and insulin levels, GTT, HOMA-IR, hepatic
insulin signaling and gene expression
GdCl3 KC depletion in Wistar rats Standard chow Not
affected
Decreased n.d. Not
affected
Hepatic and systemic IR not
affected
Glucose and insulin levels, GTT, hepatic insulin signaling [100]
HFD (60%, enriched in
MUFAs)
Decreased Increased n.d. Not
affected
Hepatic and systemic IR
increased
Glucose and insulin levels, GTT, hepatic insulin signaling
Clo liposome depletion KC HFD (60% fat) Not
affected
Decreased Not affected Not
affectedc
Hepatic IR decreased Glucose and insulin levels, HIEC, hepatic insulin
signaling
[97]
Clo liposome depletion KC HFD (59.3% fat) Increased Increased Not affected n.d. Hepatic and systemic IR
increased
Glucose and insulin levels, HOMA-IR, GTT, ITT, PTT,
hepatic insulin signaling
[101]
Clo liposome depletion KC after 10 weeks HFD HFD (60% fat) Not
affected
Decreased Not affected Not
affected
Hepatic and systemic IR not
affected
Glucose and insulin levels, HIEC, hepatic and muscle
insulin signaling
[102]
Clo liposome depletion before 4 weeks HFD HFD (60% fat) Not
affected
Decreased Decreased Decreased Hepatic and systemic IR
decreased
Glucose and insulin levels, GTT, hepatic and muscle
insulin signaling
Clo liposome depletion KC in IL-6RαLKO mice Standard chow Decreased n.d. n.d. n.d. Systemic IR decreased Insulin levels, GTT [104]
Hematopoietic PPARδ deletion with BMT
(129/SvJ mice)
HFD (60% fat) Increased Increased Increased Not
affectedd
Hepatic and systemic IR
increased
Insulin levels, GTT, ITT, hepatic, WAT and muscle insulin
signaling
[103]
HFD-induced KC activation 4 week HFD (60% fat) n.d. Not affected n.d. n.d. Hepatic IR not affected Hepatic insulin signaling [105]
8 week HFD (60% fat) n.d. Increased n.d. n.d. Hepatic IR increased Hepatic insulin signaling
HFCD-induced KC activation LDLR-/- mice HFCD (21% w/w fat, 0.2%
w/w cholesterol)
Increased Increased n.d. Increased Hepatic and systemic IR not
affected
Insulin levels, HOMA-IR, GTT, muscle and liver insulin
signaling
[106]
Neutrophil elastase knockout mice HFD (60% fat) n.d. Decreased Decreased Decreased Hepatic and systemic IR
decreased
GTT, ITT, HIEC, hepatic and WAT insulin signaling [110]
Dietary fatty acid-induced NKT-cell deﬁciency SFA enriched diet (35.9%
fat)
Increased Increased n.d. Increased Systemic IR increased GTT [111]
MUFA enriched diet (35.9%
fat)
Increased Increased n.d. Increased Systemic IR increased GTT
NKT-cell depletion by Cd1d knockdown in
mice on BALB/c background
HFD (58% fat) Increased Increased Decreased Increased Systemic IR increased Glucose levels, GTT, ITT, WAT insulin signaling [112]
Abbreviations: BMT, bonemarrow transplantation; Clo, clodronate; GdCl3, gadolinium chloride; HFCD, high fat/high cholesterol diet; HFD, high fat diet; HSD, high sucrose diet; IL-6RαLKO, interleukin-6 receptorα liver-speciﬁc knockout; KC, Kupffer
cells; LDLR-/-, low-density lipoprotein receptor knockout; MUFA, mono-unsaturated fatty acid; n.d., not determined; NKT-cell, natural killer T-cell; ref, reference; SFA, saturated fatty acid; WAT, white adipose tissue.
a All models were mice on a C57BL/6 background, unless otherwise stated.
b All percentages are calories from fat, unless otherwise stated.
c Body weight not affected, but decreased adipose tissue mass.
d Body weight not affected, but increased adipose tissue mass.
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2339N. Gruben et al. / Biochimica et Biophysica Acta 1842 (2014) 2329–2343reduction in inﬂammatory cell inﬁltration in the liver [71]. In addition,
mice deﬁcient for TLR9 or MyD88 had reduced hepatic inﬁltration of in-
ﬂammatory cells andwere protected against systemic insulin resistance
[71]. In TLR2 knockout mice, reduced hepatic inﬂammatory gene
expression and signaling were also associated with protection against
systemic and hepatic insulin resistance [72]. However, these four
mouse models also showed a reduction in body weight and/or
fat mass [71,72], which may explain the protection against insulin
resistance found in these studies. In line with this, in another study
investigating MyD88 (in which no differences in body weight were
reported),mice deﬁcient for this protein displayed an increased suscep-
tibility to the development of systemic insulin resistance [73]. Unfortu-
nately, to our knowledge, no liver-speciﬁc models regarding these
proteins and their effects on glucose metabolism have been described.
The mechanisms by which IKK2 induces insulin resistance have
been partly elucidatedwith in vitro data showing that IKK2 induces ser-
ine phosphorylation, instead of tyrosine phosphorylation, of IRS1 [74,
75]. When IRS1 is phosphorylated in this way, the insulin signaling
pathway is inhibited [76,77]. A similar mechanism is likely to play a
role in the liver. In mice with constitutively active IKK2 in the liver, Cai
et al. found that the insulin-stimulated tyrosine phosphorylation of
the IR and IRS2 was reduced in the liver [68]. Conversely, hepatic IKK2
deﬁciency resulted in improved binding of PI3K to IRS1 and IRS2 in
the liver following a high fat diet. In agreement with this, the activation
of hepatic AKT was improved in these mice [69].
Taken together, these ﬁndings show that IKK2–NF-κB activation is
involved in the development of insulin resistance. Since the in vitro
data indicate that IKK2 inhibits insulin signaling directly, the effects of
IKK2 on insulin resistance are not necessarily mediated through chang-
es in inﬂammatory endpoints. Indeed, in a study by Tamura et al. in
which NF-κB was inhibited in the liver by injecting db/db mice with
an adeno-associated virus carrying the IκBα super-repressor, mice
were protected against the development of hepatic insulin resistance
without a signiﬁcant reduction in the expression of the most important
pro-inﬂammatory cytokines in the liver [78]. Of note, in this study, the
effects on insulin resistance were independent of alterations in AKT,
IRS1 and IRS2 phosphorylation [78], indicating that other, unidentiﬁed
signaling pathways may be involved in the development of insulin re-
sistance in this model.
3.1.2. Other pathways that activate NF-κB and insulin resistance
Another major inﬂammatory pathway implicated in the develop-
ment of insulin resistance is the TNFR signaling cascade, which also
activates NF-κB [79]. In several studies, mice lacking Tnfr 1 and/or 2 or
tumor necrosis factorα (Tnfα) were protected against the development
of systemic insulin resistance [80,81]. As TNFα signaling can activate
IKK2 and JNK, TNFαmay thereby induce insulin resistance [8]. Howev-
er, several papers showed that Tnfr1- or Tnfr2-deﬁciency did not protect
against systemic insulin resistance in mice [25,82]. Moreover, Tnfr1 de-
letion in estrogen-deﬁcient mice increased systemic insulin resistance
[83]. Unfortunately, some of these studies were complicated by differ-
ences in body weight or fat mass and differences in liver inﬂammation
were not always investigated (Table 3). We recently reported that a
gain-of-function mutation in Tnfr1 did not affect body weight gain or
adipose tissue inﬂammation in mice, but did induce liver inﬂammation
and promote the progression of NAFLD to NASH [84]. Since this did not
affect hepatic or systemic insulin resistance, the inﬂammation induced
in the liver by TNFR1 activation is probably not involved in the develop-
ment of hepatic and systemic insulin resistance. Unfortunately, to our
knowledge, there is no data available on liver-speciﬁc transgenic
mouse models of Tnfα or its receptors to corroborate these ﬁndings.
There is a hepatocyte-speciﬁc model for a protein related to TNFR
signaling, TNF-receptor associated factor 2 (TRAF2) [85]. This protein
mediates the signaling transduction of TNFR and TLR to the canonical
and non-canonical NF-κB pathways and to JNK. Hepatocyte-speciﬁc
deletion of Traf2 did not affect liver inﬂammation, stressing theimportance of investigating the effect of modulations in inﬂammatory
genes on inﬂammatory endpoints. In addition, hepatic Traf2 deletion
did not affect hepatic and systemic insulin resistance. However, it did
reduce gluconeogenesis and hyperglycemia by reducing glucagon ac-
tion. This indicates that the effects of modulations in inﬂammatory
genes on glucose metabolism can be mediated by other pathways
than insulin resistance.
Recent ﬁndings have implicated a non-canonical NF-κB pathway in
mediating glucose metabolism. In this pathway, NF-κB inducing kinase
(NIK) promotes NF-κB activity, but only via speciﬁc receptors [86]. NIK
seems to be particularly important in the liver, because in severalmodels
of insulin resistance, Sheng et al. found that NIK levels were upregulated
in the liver but not inmuscle [87]. Liver-speciﬁc inhibition of this protein
improved glucosemetabolism,whereas hepatocyte-speciﬁc overexpres-
sion induced glucose intolerance [87]. Sheng et al. showed that TNFα
induced NIK activity and that NIK could directly affect glucose metabo-
lism independent of insulin resistance bymediating the glucagon action
via increased cAMP response element-binding (CREB) stability.
The receptor activator of NF-κB ligand (RANKL) is another activator
of NF-κB which is expressed in the liver [88]. Mice with a hepatocyte-
speciﬁc deletion of its receptor, Rank, and mice in which Rank was
downregulated in the liver by lentiviral administration of a short hairpin
RNA (shRNA) against Rank, were shown to be protected against high fat
diet-induced hepatic and systemic insulin resistance [89]. No changes in
body weight or fat mass were found between the groups. In mice in
which Rank was downregulated by an shRNA, NF-κB activity was
inhibited and in vitro data showed that RANKL stimulated the expres-
sion of inﬂammatory genes in hepatocytes and Kupffer cells dependent
on RANK [89], suggesting that the effects on insulin resistance in this
model are mediated through changes in inﬂammation.
3.1.3. JNK and insulin resistance
JNK is activated in response to cytokines, pathogens and cellular
stress and activates the transcription factor activator protein 1 [90].
The role of JNK in the development of hepatic insulin resistance
has been investigated in many tissue-speciﬁc mouse models. Suppres-
sion of hepatic JNK, by administering an adenovirus carrying the
dominant-negative form of Jnk or an shRNA against Jnk, improved he-
patic insulin sensitivity without affecting body weight gain [91,92]. In
line with this, overexpression of the wild type form of Jnk in the liver
produced the opposite result, without alterations in body weight gain
[91]. Unfortunately, this study did not examine the effects of modiﬁca-
tions in Jnk on inﬂammation and steatosis. The mechanisms by which
JNK is believed to induce insulin resistance are similar to those found
to play a role with IKK2. In cell culture studies, JNKwas shown to induce
serine phosphorylation of IRS1 [75,93]. This has also been shown to
occur in the liver of mice overexpressing JNK [91].
However alterations in JNK-induced NF-κB activation do not consis-
tently affect inﬂammation and insulin resistance as one would expect.
For example, mice inwhich Jnkwas deleted in hepatocytes paradoxical-
ly have increased inﬂammation, steatosis and are more insulin resistant
in the liver compared to wild type mice, without any changes in fat or
lean mass [94]. The paradoxical increase in inﬂammation in this model
underscores the importance of including inﬂammatory endpoints,
such as cytokines, chemokines and markers for macrophages and
Kupffer cells in future studies. In addition, in this study, hepatocyte-
speciﬁc deletion of Jnk also increased insulin clearance, providing
another example of how alterations in inﬂammatory genes affect the
glucose metabolism independent of insulin resistance.
3.1.4. Kupffer cells and insulin resistance
Kupffer cells are the resident macrophages of the liver and they are
thought to play an important role in the regulation of hepatic inﬂamma-
tion. They amount to approximately 10% of the total number of cells in
the liver. They recognize exogenous and endogenous molecular signals,
such as microbes or cytokines, and they initiate several responses in
2340 N. Gruben et al. / Biochimica et Biophysica Acta 1842 (2014) 2329–2343reaction to this. These include the release of cytokines and chemokines,
the recruitment of new macrophages or other immune cells, engulf-
ment of cells and cell debris, and the presentation of antigens to the
adaptive immune system. Kupffer cells also respond to alterations in
lipid accumulation and activate inﬂammatory pathways (reviewed by
[95]). These cells are therefore thought to be particularly important in
maintaining liver homeostasis and regulating liver inﬂammation.
Kupffer cells probably induce insulin resistance through interactions
with hepatocytes. For example, classically activated (M1) Kupffer cells
were shown to inhibit insulin signaling in hepatocytes [96]. This effect
was probably mediated through TNFα secretion, as inhibition of TNFα
attenuated the effect of Kupffer cells on hepatocytes [96]. Several
other studies showed a decrease in pro-inﬂammatory cytokine expres-
sion in the liver after depletion of Kupffer cells [97,98]. These pro-
inﬂammatory cytokines activate IKK2 and JNK in hepatocytes and
thereby induce insulin resistance. In addition, activation of isolated
Kupffer cells was shown to induce insulin resistance by the secretion
of oncostatin M (OSM). OSM activated the suppressor of cytokine sig-
naling 3 (SOCS3) in hepatocytes, which attenuated the phosphorylation
of AKT and thereby inhibited insulin signaling [99].
Many studies have investigated the role of Kupffer cell depletion
in the development of insulin resistance with conﬂicting results
(Table 4). Several papers show that this improves hepatic insulin resis-
tance [96–98], whereas others have shown a deterioration of hepatic
and systemic insulin resistance [100,101]. Itwas also shown that deplet-
ing Kupffer cells before the start of a high fat diet could prevent hepatic
and systemic insulin resistance, but the depletion did not improve insu-
lin resistance once it had developed [102]. In some studies, differences
in body weight gain and/or fat mass following Kupffer cell depletion
could not be excluded as a confounding factor (Table 4). It is possible
that the activation status of the Kupffer cells determineswhether deple-
tion can impair or improve insulin signaling. Alternative M2 activation
of Kupffer cells was shown to improve hepatic and systemic insulin re-
sistance inmice [103]. In the two studies inwhich insulin resistancewas
exacerbated by Kupffer cell depletion, Kupffer cells were alternatively
activated before depletion [100,101].
Nevertheless, studies investigating Kupffer cell activation and
insulin resistance raise further controversy. Liver-speciﬁc ablation of
interleukin-6 receptorα (Il-6Rα) resulted in an exaggerated inﬂamma-
tory response and glucose intolerance in mice. Depletion of their
Kupffer cells ameliorated glucose intolerance [104]. In another study,
it was shown that Kupffer cells became activated within 4 weeks of a
high fat diet, through reduced nitric oxide signaling [105]. However,
this did not simultaneously result in the development of hepatic insulin
resistance at the level of IRS-1/AKT signaling, which only started after
8 weeks of high fat diet [105]. After 8 weeks the Kupffer cells were
activated to a similar extent as at 4 weeks, but inﬂammation in the
whole liver was now observed [105]. This may indicate that Kupffer
cell activation does not by itself induce insulin resistance, but that it
depends on the interaction between Kupffer cells and hepatocytes and
the subsequent activation of inﬂammation in hepatocytes.
In contrast, we recently found that severe inﬂammation in thewhole
liver does not induce insulin resistance [106]. Low-density lipoprotein
receptor knockout mice fed a high fat, high cholesterol diet developed
severe liver inﬂammation, driven by cholesterol-induced Kupffer cell
activation [107,108], but they did not develop hepatic or systemic insu-
lin resistance following 2 and 15 weeks on such a diet [106]. Thus,
Kupffer cell activation does not always lead to insulin resistance.
Whether Kupffer cells induce insulin resistance, may depend on how
they are activated and on their inﬂammatory status. In addition, their
effect on insulin resistance is likely to be indirect, as it could depend
on their ability to activate inﬂammatory pathways within hepatocytes.
3.1.5. Other immune cells in the liver and insulin resistance
Studies have reported that neutrophils have inﬁltrated the liver in
patients with NASH [109]. This was later conﬁrmed in mice fed on ahigh fat diet [110]. Ablation of the expression of neutrophil elastase re-
duced the amount of neutrophils in the liver and resulted in a reduction
in hepatic inﬂammation and hepatic as well as systemic insulin
resistance [110]. However, in this study, adipose tissue neutrophils
and macrophages were also reduced, so the improvements in glucose
tolerance could be due to changes in the liver, or adipose tissue, or both.
Lastly, the role of hepatic natural killer T (NKT)-cells in the develop-
ment of insulin resistance was investigated by Hua et al. [111]. They re-
ported that a diet enriched inMUFAs or SFAs resulted in fewer NKT cells
in the liver. This was associatedwith amore pro-inﬂammatory cytokine
release and the development of glucose intolerance. These results agree
with those from a recent study by Martin-Murphy et al., who found a
depletion of NKT cells by knockdown of Cd1d resulted in hepatic inﬂam-
mation and systemic insulin resistance [112]. However, differences in
steatosis and body weight cannot be excluded as confounding factors
in these studies [111,112].
3.2. Hepatic inﬂammation and insulin resistance: unresolved questions
Despite the tight association between low-grade chronic inﬂamma-
tion and insulin resistance, evidence from numerous mouse models
suggests that inﬂammation in the liver does not drive insulin resistance
(Tables 3 and 4, Fig. 2). Some mice that have a reduction in hepatic in-
ﬂammation are even more susceptible to insulin resistance, indicating
that factors besides inﬂammation cause insulin resistance in the mice.
Similar to the effect of lipids, whether hepatic inﬂammation induces in-
sulin resistance seems to depend on the circumstances under which it
occurs. Conditions that are likely to be of importance are the duration
and the level of inﬂammation. In addition, changes in the inﬂammatory
pathways may affect glucose metabolism through mechanisms other
than insulin resistance. In several mouse models, alterations in glucose
metabolism were mediated by glucagon [85,87]. Because these alter-
ations appear to be similar to insulin resistance at ﬁrst sight, it is impor-
tant to thoroughly investigate glucose homeostasis and determine if the
insulin signaling is affected. The discrepancies between the studies may
also be explained by effects on adipose tissue inﬂammation, as these
have not always been reported (Table 3). In addition, the role of Kupffer
cells in the development of insulin resistance is still controversial.
Although, in some cases, the differences between the effects of Kupffer
cell depletion could be explained by their activation status, a pro-
inﬂammatory activation does not necessarily induce insulin resistance.
This can be partly explained by the ability of Kupffer cells to activate
inﬂammatory pathways in hepatocytes.
4. Concluding remarks
The role of NAFLD in the development of insulin resistance remains
controversial, even when comparing studies in which bodyweight gain
has been ruled out as a confounding factor. In general, we believe that
NAFLD cannot be considered to be one of themain drivers of insulin re-
sistance in mice, but there is more likely to be a dangerous liaison be-
tween the two. Whether this is also the case in human NAFLD remains
to be determined. As alterations in body weight or fat mass appear to
be a driving factor in the intricate relationship between NAFLD and sys-
temic aswell as hepatic insulin resistance inmany studies, this supports
the idea that adiposity is more important than NAFLD in the etiology of
insulin resistance. On the one hand steatosis, inﬂammation and insulin
resistance may simply be correlated via the common driver of obesity,
suggesting that there is no causal relationship in either direction,
while, on the other hand, it is possible that NAFLD only causes insulin
resistance under certain circumstances. These circumstances are likely
to include environmental factors, such as gut microbiota and dietary
composition. In addition, the intracellular localization of lipids, fatty
acid composition in the liver, and the amount and duration of inﬂam-
mation may determine if NAFLD causes insulin resistance. Moreover, it
may also depend on whether adipose tissue inﬂammation is affected.
2341N. Gruben et al. / Biochimica et Biophysica Acta 1842 (2014) 2329–2343To further investigate the circumstances under which NAFLD causes
insulin resistance, we recommend taking lipid species and their locali-
zation into account as markers of steatosis in future studies. We further
consider it important to measure inﬂammatory endpoints (such as cy-
tokines, chemokines, and markers for macrophages and Kupffer cells)
to determinewhether modulations in the pathways involved in inﬂam-
mation actually alter the levels of inﬂammation. Since inﬂammation is
tightly controlled, the many negative-feedback pathways that regulate
it could interfere with the outcome and detailed measurements might
lead to surprising results. In this respect, it is also important to measure
if inﬂammation in adipose tissue is affected. Moreover, discrepancies
between the various reports offer an opportunity to investigate the un-
derlying differences and to learn more about the role of environmental
factors in the disease process. For example, NAFLD is associatedwith in-
sulin resistance in somemodels of the disease, but not in all. It would be
interesting to investigate what underlies the differences between these
NAFLDmodels. Finally, by studyingmore liver-speciﬁcmodels and gain-
of-function models, greater insight into the role of NAFLD in insulin
resistance will be obtained. We are certain that, with the techniques
now available, many factors that play a role in the etiology of insulin
can be elucidated in the near future.
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